Geode Capital Management LLC Purchases 66,170 Shares of Quince Therapeutics, Inc. (NASDAQ:QNCX)

Geode Capital Management LLC increased its position in shares of Quince Therapeutics, Inc. (NASDAQ:QNCX) by 24.2% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 339,125 shares of the company’s stock after buying an additional 66,170 shares during the quarter. Geode Capital Management LLC owned 0.78% of Quince Therapeutics worth $263,000 as of its most recent SEC filing.

Quince Therapeutics Trading Down 3.4 %

Shares of QNCX opened at $1.73 on Tuesday. Quince Therapeutics, Inc. has a 52-week low of $0.51 and a 52-week high of $2.45. The business’s fifty day moving average is $1.86 and its 200-day moving average is $1.16. The company has a debt-to-equity ratio of 0.33, a quick ratio of 9.53 and a current ratio of 9.53. The firm has a market cap of $76.12 million, a price-to-earnings ratio of -1.40 and a beta of 0.64.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. RODMAN&RENSHAW upgraded Quince Therapeutics to a “strong-buy” rating in a report on Tuesday, October 29th. Rodman & Renshaw started coverage on Quince Therapeutics in a report on Tuesday, October 29th. They set a “buy” rating and a $11.00 price objective for the company. Brookline Capital Management started coverage on Quince Therapeutics in a research report on Wednesday, December 18th. They set a “buy” rating and a $9.00 price target for the company. Maxim Group started coverage on Quince Therapeutics in a research report on Thursday, November 7th. They set a “buy” rating and a $6.00 price target for the company. Finally, D. Boral Capital reissued a “buy” rating and set a $12.00 price target on shares of Quince Therapeutics in a research report on Thursday, January 2nd. Four analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, Quince Therapeutics presently has an average rating of “Buy” and a consensus target price of $9.50.

Quince Therapeutics Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.